Angioedema: A High-Yield USMLE Review

Angioedema is rapid, deep dermal and submucosal swelling that classically involves the face, lips, and oropharynx and can threaten the airway. On exams you must separate it by mechanism into histamine/IgE-mediated (Type I, mast cell) angioedema and bradykinin-mediated angioedema. Bradykinin-mediated disease includes ACE inhibitor–induced angioedema and C1 esterase inhibitor (C1-INH) deficiency—hereditary (autosomal dominant) and acquired. Getting the mechanism right dictates both the diagnostic workup and the correct management move.

Presentation

• Rapid oropharyngeal swelling that can produce sudden-onset stridor and belongs in the differential for acute airway compromise
• Type I (IgE/histamine-mediated) presentations come on within minutes of an allergen, travel with urticaria and pruritus, and at the extreme progress to anaphylaxis
• Bradykinin-mediated angioedema (ACE inhibitor–induced or C1-INH deficiency) is characteristically NON-pruritic and NOT accompanied by urticaria
• In a patient on an ACE inhibitor, swelling can appear days to years after starting the drug and may recur unpredictably
• Hereditary angioedema presents with recurrent episodes of swelling (face, extremities, larynx) plus painful, self-limited abdominal attacks from bowel wall edema, often beginning in childhood/adolescence and sometimes triggered by trauma or stress

Diagnosis

• The diagnosis is largely clinical—distinguish histaminergic from bradykinin-mediated disease by the presence or absence of urticaria/pruritus and the tempo and triggers
• Review the medication list: an ACE inhibitor (or ARNI) in the setting of non-pruritic, non-urticarial angioedema points to a bradykinin mechanism
• For recurrent angioedema without urticaria, obtain a complement screen—a low C4 is the best screening test and prompts measurement of C1-INH level and function
• Hereditary angioedema type I: low C1-INH level and function with low C4; type II: normal/elevated C1-INH level but low function with low C4
• Acquired C1-INH deficiency (associated with lymphoproliferative/autoimmune disease) shows low C1-INH and low C4 plus a characteristically low C1q, which distinguishes it from hereditary disease
• Characterize the tempo—a Type I (minutes; urticaria/anaphylaxis) reaction is mechanistically distinct and behaves very differently on re-exposure than bradykinin-mediated swelling

Management

• When rapid swelling threatens the airway, secure the airway first; diagnostics and further treatment follow
• Type I / anaphylactic (histaminergic) angioedema: treat with intramuscular epinephrine, plus antihistamines and corticosteroids as adjuncts
• Bradykinin-mediated angioedema does NOT respond reliably to epinephrine, antihistamines, or steroids—recognizing the mechanism prevents ineffective treatment
• ACE inhibitor–induced angioedema: stop the ACE inhibitor immediately and avoid it permanently; provide supportive airway management, and use targeted agents (icatibant, C1-INH concentrate) for severe or airway-threatening attacks
• Acute hereditary/acquired C1-INH deficiency attacks: treat with C1 esterase inhibitor concentrate, the bradykinin B2-receptor antagonist icatibant, or the kallikrein inhibitor ecallantide
• Hereditary angioedema prophylaxis (not acute treatment): C1-INH replacement, kallikrein inhibitors (e.g., lanadelumab), or attenuated androgens such as danazol
• In a patient with a history of angioedema, drop the ACE inhibitor from consideration entirely and select an alternative antihypertensive
• When switching from an ACE inhibitor to ARNI, enforce a 36-hour washout to avoid overlapping bradykinin elevation and angioedema

High-yield

• Bradykinin-mediated angioedema (ACE inhibitor, hereditary, acquired) is NON-pruritic and lacks urticaria—unlike histaminergic Type I disease
• Type I angioedema is IgE/histamine-mediated, appears within minutes, clusters with urticaria and anaphylaxis, and is treated with epinephrine
• Low C4 is the screening test for C1 esterase inhibitor deficiency; confirm with C1-INH level and function
• Hereditary angioedema is autosomal dominant C1-INH deficiency; acquired C1-INH deficiency additionally shows LOW C1q (associated with lymphoproliferative/autoimmune disease)
• Acute HAE attacks are treated with C1-INH concentrate, icatibant (B2-receptor antagonist), or ecallantide (kallikrein inhibitor)—NOT epinephrine, antihistamines, or steroids
• ACE inhibitor angioedema can appear days to years after starting the drug and mandates permanent discontinuation
• ARNI replaces (never is added to) an ACE inhibitor, requiring a 36-hour washout because both elevate bradykinin
• A prior history of angioedema removes the ACE inhibitor from first-line hypertension options

Pitfalls

• Assuming all angioedema is allergic—giving epinephrine, antihistamines, and steroids for bradykinin-mediated disease (ACE inhibitor or C1-INH deficiency), which respond poorly to those agents
• Forgetting hereditary/acquired C1-INH deficiency in recurrent, non-urticarial angioedema and failing to order a C4 level
• Confusing acquired with hereditary C1-INH deficiency—only acquired disease shows a low C1q and presents later in life with an underlying lymphoproliferative/autoimmune disorder
• Attributing angioedema to something other than an ACE inhibitor because it started long after the drug was begun—onset can be delayed by years
• Adding ARNI on top of (or too soon after) an ACE inhibitor, stacking two bradykinin-elevating mechanisms
• Anchoring on croup when a child has rapid oropharyngeal swelling—consider angioedema, especially recurrent episodes suggesting hereditary disease